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Understanding the shape and strength of risk factor asso-
ciations with disease in observational studies is essential
for the successful design of risk factor-modification trials.
Observational studies show that low plasma levels of
25-hydroxy vitamin D (25[OH]D), a blood marker of
vitamin D status, are linearly related with bone mineral
density and fractures, in addition to higher risks of vascu-
lar and non-vascular mortality. Over the last 20 years,
several trials of vitamin D3 have assessed the effects of
supplementation with equivalent daily doses of 400-800
IU on risk of fracture, but results have been conflicting.
A meta-analysis of such trials reported a 14% (95%CI
4-23%) reduction in non-vertebral fractures, but the
results suggest that plasma levels of 25[OH]D need to be
at least 80-90 nmol/L to provide fracture protection.
Moreover, previous trials also indicate an average
increase of only about 7-10 nmol/L in plasma 25[OH]D
for each 400 IU of vitamin D3 given daily. Consequently,
at least 2000 IU daily may be required to increase plasma
levels of 25(OH)D from an average winter level of
30 nmol/L (typical in the UK) to 90 nmol/L, suggesting
that the previous trials have used insufficient doses of
vitamin D3 to detect the epidemiologically predicted dif-
ferences in clinical outcomes. To help determine the
optimum dose of vitamin D3 for prevention of fractures
and other health outcomes, we are comparing the bio-
chemical efficacy and safety of 2000 and 4000 IU daily
(versus placebo) vitamin D3 in a pilot study of 305
healthy people aged >65 years.
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